US Stocks Movement | AstraZeneca (AZN.US) rises over 2% as Goldman Sachs is bullish, raising price target to $99
According to Jinse Finance APP, on Wednesday, AstraZeneca (AZN.US) rose more than 2%, closing at $81.99. Recently, Goldman Sachs released a research report stating that AstraZeneca announced positive results for Baxdrostat in the Phase III BaxHTN clinical trial at the 2025 European Society of Cardiology (ESC) annual meeting. Baxdrostat demonstrated strong efficacy in treating hypertension during the clinical trial and is expected to bring AstraZeneca sales opportunities worth several billions of dollars. Goldman Sachs has given AstraZeneca a "Buy" rating, with a 12-month target price of $99. This target price represents an upside of about 23% compared to the stock's closing price of $80.19 on Tuesday.
According to the information, Baxdrostat is a highly selective aldosterone synthase inhibitor (ASI) that targets one of the hormones responsible for increased blood pressure and elevated cardiovascular and renal risks. Currently, the drug is undergoing clinical trials worldwide, with more than 20,000 patients enrolled. The trials include monotherapy for hypertension and primary aldosteronism, combination therapy with dapagliflozin for chronic kidney disease and hypertension, as well as prevention of heart failure in hypertensive patients. It is reported that Baxdrostat is expected to be approved in the US and Europe in the first half of 2026, becoming the world's first marketed aldosterone synthase inhibitor (ASI) antihypertensive drug.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Phishing Risks in DeFi: What Investors Must Do to Protect Their Assets
- DeFi phishing attacks now account for 56.5% of breaches in 2025, surpassing technical exploits as the sector's top security threat. - 2025 phishing losses exceeded $410M, with AI-generated scams achieving 54% click-through rates and triggering market instability like the Venus Protocol $13.5M incident. - Investors must adopt institutional custody solutions, prioritize user education, and demand governance upgrades to combat phishing risks undermining DeFi's trustless model. - Cybercriminals increasingly
Is Bitcoin’s ETF-Driven Growth Sustainable Amid Shifting Institutional Demand?
- -2025 institutional crypto demand shows Bitcoin ETFs rebounding with $33.6B holdings, while Ethereum ETFs face volatile inflows/outflows. - -Bitcoin's zero-yield model contrasts with Ethereum's 6% staking returns under the CLARITY Act, driving dual-asset allocation strategies. - -Ethereum's deflationary tokenomics and regulatory clarity attract 59% of institutions planning >5% crypto allocations in 2025. - -Solana/XRP ETFs gain traction with $311M combined inflows, reflecting diversification into high-gr
MoonBull ($MOBU): The Whitelist-Driven Meme Coin 2.0 with 1000x Potential
- MoonBull ($MOBU) redefines meme coins with structured incentives, Ethereum-based scalability, and institutional-grade security, positioning as a 1000x opportunity in 2025. - Its tokenomics allocate 30% to liquidity pools, 20% for 66-80% APY staking rewards, and 2% auto-burn per transaction, creating a self-sustaining flywheel effect. - Leveraging Ethereum Layer 2 infrastructure (Arbitrum/Base), MoonBull achieves 10,000 TPS and 53% lower gas fees, enabling seamless DeFi integration and institutional credi
Ethereum's Institutional Adoption: A Strategic Asset in Web3 Expansion
- Ethereum's 4.5–5.2% staking yields and 2025 SEC reclassification as a utility token drove $9.4B ETF inflows and 29.6% supply staked by institutions. - 53.14% of $26.63B RWA tokenization market relies on Ethereum, with BlackRock and Goldman Sachs tokenizing $10.8B U.S. Treasuries and $8.32B gold. - DeFi TVL surged to $223B in 2025 via L2 scalability, enabling institutional yield generation through tokenized RWAs and programmable finance. - Regulatory clarity under GENIUS Act and Ethereum's deflationary su
Trending news
MoreCrypto prices
More
